Table 2.
Subgroup | No. studies | No. patients | Fixed-effects model | Heterogeneity | ||
---|---|---|---|---|---|---|
HR (95% CI) | P-value | I2 (%) | PH-value | |||
Tumor Site | ||||||
PCa | 2 | 558 | 2.26 (1.47-3.48) | <0.001 | 2.7 | 0.311 |
RCC | 6 | 3171 | 2.13 (1.75-2.61) | <0.001 | 5.1 | 0.384 |
UTUC | 3 | 832 | 2.34 (1.81-3.02) | <0.001 | 0 | 0.811 |
Ethnicity | ||||||
Asian | 6 | 2878 | 2.07 (1.73-2.49) | <0.001 | 0 | 0.490 |
Caucasian | 5 | 1683 | 2.52 (1.95-3.25) | <0.001 | 0 | 0.893 |
Cut-off value | ||||||
<350mg/dl | 5 | 2055 | 1.91(1.52-2.40) | <0.001 | 0 | 0.858 |
≥350mg/dl | 6 | 2506 | 2.46(2.03-2.98) | <0.001 | 0 | 0.707 |
Overall | 11 | 4561 | 2.21(1.91-2.57) | <0.001 | 0 | 0.723 |
OS: overall survival, HR: hazard ratio, CI: confidence interval, PH: P for heterogeneity, PCa: prostate cancer, RCC: renal cell carcinoma, UTUC: upper tract urothelial carcinoma.